EMEA-003121-PIP01-21
Key facts
Invented name |
Flebogamma DIF (previously Flebogammadif)
|
Active substance |
Human normal immunoglobulin
|
Therapeutic area |
Immunology-Rheumatology-Transplantation
|
Decision number |
P/0094/2022
|
PIP number |
EMEA-003121-PIP01-21
|
Pharmaceutical form(s) |
All pharmaceutical forms
|
Condition(s) / indication(s) |
Treatment of post-polio syndrome
|
Route(s) of administration |
All routes of administration
|
Contact for public enquiries |
Instituto Grifols, S.A.
E-mail: areatecnica.instituto@grifols.com |
Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|